Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels

ACS Chemical Neuroscience

Volumn 8, Issue 6, 2017, Pages 1170-1176

  Horvath, Istvan ^a   Iashchishyn, Igor A ^a,b   Forsgren, Lars ^a   Morozova Roche, Ludmilla A ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SUMY STATE UNIVERSITY   (Ukraine)

Author keywords

Biomarkers; blood plasma; cerebrospinal fluid; enzyme linked immunosorbent assay (ELISA); Parkinson's disease; synuclein autoantibodies

Indexed keywords

ALPHA SYNUCLEIN; AUTOANTIBODY; AUTOANTIGEN;

ADULT; AGED; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCHEMISTRY; MALE; NONPARAMETRIC TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CEREBROSPINAL FLUID; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 85021104422     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.7b00063     Document Type: Article

References (35)

1. de Lau, L. M. and Breteler, M. M. (2006) Epidemiology of Parkinson's disease Lancet Neurol. 5, 525-535 10.1016/S1474-4422(06)70471-9
2. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies Nature 388, 839-840 10.1038/42166
3. Adler, C. H., Beach, T. G., Hentz, J. G., Shill, H. A., Caviness, J. N., Driver-Dunckley, E., Sabbagh, M. N., Sue, L. I., Jacobson, S. A., Belden, C. M., and Dugger, B. N. (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study Neurology 83, 406-412 10.1212/WNL.0000000000000641
4. Schapira, A. H. (1999) Science, medicine, and the future: Parkinson's disease BMJ. 318, 311-314 10.1136/bmj.318.7179.311
5. Gerlach, M., Maetzler, W., Broich, K., Hampel, H., Rems, L., Reum, T., Riederer, P., Stoffler, A., Streffer, J., and Berg, D. (2012) Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics J. Neural. Transm. 119, 39-52 10.1007/s00702-011-0682-x
6. Gruden, M. A., Sewell, R. D. E., Yanamandra, K., Davidova, T. V., Kucheryanu, V. G., Bocharov, E. V., Bocharova, O. R., Polyschuk, V. V., Sherstnev, V. V., and Morozova-Roche, L. A. (2011) Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression J. Neuroimmunol. 233, 221-227 10.1016/j.jneuroim.2010.12.001
7. Gruden, M. A., Yanamandra, K., Kucheryanu, V. G., Bocharova, O. R., Sherstnev, V. V., Morozova-Roche, L. A., and Sewell, R. D. (2012) Correlation between protective immunity to alpha-synuclein aggregates, oxidative stress and inflammation NeuroImmunoModulation 19, 334-342 10.1159/000341400
8. Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., and Morozova-Roche, L. A. (2011) α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients PLoS One 6, e18513 10.1371/journal.pone.0018513
9. Koehler, N. K. U., Stransky, E., Shing, M., Gaertner, S., Meyer, M., Schreitmüller, B., Leyhe, T., Laske, C., Maetzler, W., Kahle, P., Celej, M. S., Jovin, T. M., Fallgatter, A. J., Batra, A., Buchkremer, G., Schott, K., and Richartz-Salzburger, E. (2013) Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease PLoS One 8, e64649 10.1371/journal.pone.0064649
10. Maetzler, W., Apel, A., Langkamp, M., Deuschle, C., Dilger, S. S., Stirnkorb, J. G., Schulte, C., Schleicher, E., Gasser, T., and Berg, D. (2014) Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls PLoS One 9, e88604 10.1371/journal.pone.0088604
11. Maetzler, W., Berg, D., Synofzik, M., Brockmann, K., Godau, J., Melms, A., Gasser, T., Hornig, S., and Langkamp, M. (2011) Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias J. Alzheimers Dis. 26, 171-179 10.3233/JAD-2011-110221
12. Woulfe, J. M., Duke, R., Middeldorp, J. M., Stevens, S., Vervoort, M., Hashimoto, M., Masliah, E., Chan, P., Di Monte, D. A., Langston, J. W., Petzinger, G., Hoogendoorn, H., and Munoz, D. G. (2002) Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD Neurology 58, 1435-1436 10.1212/WNL.58.9.1435
13. Besong-Agbo, D., Wolf, E., Jessen, F., Oechsner, M., Hametner, E., Poewe, W., Reindl, M., Oertel, W. H., Noelker, C., Bacher, M., and Dodel, R. (2013) Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease Neurology 80, 169-175 10.1212/WNL.0b013e31827b90d1
14. Bryan, T., Luo, X., Forsgren, L., Morozova-Roche, L. A., and Davis, J. J. (2012) The robust electrochemical detection of a Parkinson's disease marker in whole blood sera Chem. Sci. 3, 3468-3473 10.1039/c2sc21221h
15. Xu, Q., Evetts, S., Hu, M., Talbot, K., Wade-Martins, R., and Davis, J. J. (2014) An impedimetric assay of α-synuclein autoantibodies in early stage Parkinson's disease RSC Adv. 4, 58773-58777 10.1039/C4RA10100F
16. Heinzel, S., Gold, M., Deuschle, C., Bernhard, F., Maetzler, W., Berg, D., and Dodel, R. (2014) Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (Error) variance in biomarker Assays PLoS One 9, e114566 10.1371/journal.pone.0114566
17. Smith, L. M., Schiess, M. C., Coffey, M. P., Klaver, A. C., and Loeffler, D. A. (2012) α-synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls PLoS One 7, e52285 10.1371/journal.pone.0052285
18. Papachroni, K. K., Ninkina, N., Papapanagiotou, A., Hadjigeorgiou, G. M., Xiromerisiou, G., Papadimitriou, A., Kalofoutis, A., and Buchman, V. L. (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease J. Neurochem. 101, 749-756 10.1111/j.1471-4159.2006.04365.x
19. Horvath, I., Jia, X., Johansson, P., Wang, C., Moskalenko, R., Steinau, A., Forsgren, L., Wågberg, T., Svensson, J., Zetterberg, H., and Morozova-Roche, L. A. (2016) Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer's disease ACS Chem. Neurosci. 7, 34-39 10.1021/acschemneuro.5b00265
20. Zetterberg, H. (2015) Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments Curr. Opin. Psychiatry. 28, 402-409 10.1097/YCO.0000000000000179
21. Nakagawa, S. and Cuthill, I. C. (2007) Effect size, confidence interval and statistical significance: a practical guide for biologists Biol. Rev. Camb. Philos. Soc. 82, 591-605 10.1111/j.1469-185X.2007.00027.x
22. Cliff, N. (1993) Dominance statistics: Ordinal analyses to answer ordinal questions Psychol. Bull. 114, 494 10.1037/0033-2909.114.3.494
23. Cohen, J. (1988) Statistical power analysis for the behavioral sciences, L. Erlbaum Associates, Hillsdale, N.J.
24. Hall, S., Ohrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Wildner, H., Decraemer, H., Nagga, K., Minthon, L., Londos, E., Vanmechelen, E., Holmberg, B., Zetterberg, H., Blennow, K., and Hansson, O. (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders Arch. Neurol. 69, 1445-1452 10.1001/archneurol.2012.1654
25. Hughes, A. J., Daniel, S. E., Kilford, L., and Lees, A. J. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J. Neurol., Neurosurg. Psychiatry 55, 181-184 10.1136/jnnp.55.3.181
26. Burtis, C. A., Ashwood, E. R., and Bruns, D. E. (2006) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4 th ed., Elsevier Saunders, St. Louis, MO.
27. Obermeier, B., Daneman, R., and Ransohoff, R. M. (2013) Development, maintenance and disruption of the blood-brain barrier Nat. Med. 19, 1584-1596 10.1038/nm.3407
28. Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., Nagelhus, E. A., and Nedergaard, M. (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β Sci. Transl. Med. 4, 147ra111 10.1126/scitranslmed.3003748
29. Braak, H., de Vos, R. A., Bohl, J., and Del Tredici, K. (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology Neurosci. Lett. 396, 67-72 10.1016/j.neulet.2005.11.012
30. Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z. Y., Roybon, L., Melki, R., and Li, J. Y. (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats Acta Neuropathol. 128, 805-820 10.1007/s00401-014-1343-6
31. Roodveldt, C., Christodoulou, J., and Dobson, C. M. (2008) Immunological features of alpha-synuclein in Parkinson's disease J. Cell. Mol. Med. 12, 1820-1829 10.1111/j.1582-4934.2008.00450.x
32. Schneeberger, A., Mandler, M., Mattner, F., and Schmidt, W. (2012) Vaccination for Parkinson's disease Parkinsonism Relat. Disord. 18, S11-S13 10.1016/S1353-8020(11)70006-2
33. Bae, E. J., Lee, H. J., Rockenstein, E., Ho, D. H., Park, E. B., Yang, N. Y., Desplats, P., Masliah, E., and Lee, S. J. (2012) Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission J. Neurosci. 32, 13454-13469 10.1523/JNEUROSCI.1292-12.2012
34. Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T. T., Mueller-Steiner, S., Seubert, P., Barbour, R., McConlogue, L., Buttini, M., Games, D., and Schenk, D. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease PLoS One 6, e19338 10.1371/journal.pone.0019338
35. Sharma, S. K., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., and Wittung-Stafshede, P. (2015) Insulin-degrading enzyme prevents alpha-synuclein fibril formation in a nonproteolytical manner Sci. Rep. 5, 12531 10.1038/srep12531